Skip to content

Protagonist Therapeutics PTGX Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$198.6M+10.6%
Eli Lilly logo
Eli LillyLLY
Incyte logo
IncyteINCY
AbbVie logo
AbbVieABBV
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
Kymera Therapeutics logo
Kymera TherapeuticsKYMR

Other financials

Income statement

See full
Revenue$56.4M+99.0%
Operating income-$3.6M+81.1%
Net income$3.8M+132%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$193.7M+38.7%
Total debt$9.8M-13.9%
Total equity$655.5M-4.9%
Total assets$697.5M-6.0%

Cash flow

See full
Operating cash flow-$48.9M-139%
CapEx$215.0K-60.6%
Free cash flow-$49.2M-139%

Valuation

See full
Market cap$7.26B+127%
Enterprise value$7.07B+130%
P/S98×+82.6×

Profitability

See full
Operating margin-192.4%-205pp
Net margin-154.9%-182pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity-17.1%-26.1pp
Debt / equity0.0×
Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Protagonist Therapeutics's increase (decrease) in prepaid expense and other assets?
Protagonist Therapeutics (PTGX) reported increase (decrease) in prepaid expense and other assets of $1.92M in Q1 2026.
How has Protagonist Therapeutics's increase (decrease) in prepaid expense and other assets changed year-over-year?
Protagonist Therapeutics's increase (decrease) in prepaid expense and other assets increased by 102.3% year-over-year, from $948K to $1.92M.
What is the long-term trend for Protagonist Therapeutics's increase (decrease) in prepaid expense and other assets?
Over 3 years (2021 to 2025), Protagonist Therapeutics's increase (decrease) in prepaid expense and other assets has grown at a -9.3% compound annual growth rate (CAGR), from $3.23M to $2.41M.
What does increase (decrease) in prepaid expense and other assets mean?
This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.